Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
03/22/2023 | Allogene Therapeutics, Inc. | ALLO | Grant | Common Stock | 1.3M | $0.00 | $0 | | 03/22/2023 |
03/22/2023 | Allogene Therapeutics, Inc. | ALLO | Grant | Stock Option (Right to Buy) | 994.8k | $5.04 | $5M | | 03/22/2023 |
09/14/2022 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 160k | $5.00 | $800k | | 09/14/2022 |
08/31/2022 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 3.2k | $5.00 | $16.2k | | 08/31/2022 |
06/22/2022 | Kronos Bio, Inc. | KRON | Grant | Stock Option (Right to Buy) | 34k | $3.53 | $120k | | 06/22/2022 |
06/10/2022 | Ginkgo Bioworks Holdings, Inc. | | Grant | Class A Common Stock | 70.9k | $0.00 | $0 | | 06/10/2022 |
06/10/2022 | Ginkgo Bioworks Holdings, Inc. | | Grant | Stock Option | 108.5k | $2.82 | $306k | | 06/10/2022 |
06/08/2022 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (right to buy) | 10k | $7.06 | $70.6k | | 06/08/2022 |
03/23/2022 | Allogene Therapeutics, Inc. | ALLO | Grant | Stock Option (Right to Buy) | 1.5M | $9.69 | $14.1M | | 03/23/2022 |
03/14/2022 | Allogene Therapeutics, Inc. | ALLO | Other (acquisition) | Common Stock | 4.7M | $0.00 | $0 | See footnote | 03/14/2022 |
03/14/2022 | Allogene Therapeutics, Inc. | ALLO | Other (disposition) | Common Stock | 4.7M | $0.00 | $0 | See footnote | 03/14/2022 |
03/14/2022 | Allogene Therapeutics, Inc. | ALLO | Other (disposition) | Common Stock | 4.7M | $0.00 | $0 | See footnote | 03/14/2022 |
03/14/2022 | Allogene Therapeutics, Inc. | ALLO | Other (acquisition) | Common Stock | 4.7M | $0.00 | $0 | See footnote | 03/14/2022 |
01/12/2022 | Allogene Therapeutics, Inc. | ALLO | Purchase | Common Stock | 155k | $12.60 | $2M | See footnote | 01/12/2022 |
06/22/2021 | Kronos Bio, Inc. | KRON | Grant | Stock Option (Right to Buy) | 20.6k | $24.18 | $498.1k | | 06/22/2021 |
06/07/2021 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (right to buy) | 10k | $17.98 | $179.8k | | 06/07/2021 |
05/24/2021 | Allogene Therapeutics, Inc. | ALLO | Exercise | Stock Option (Right to Buy) | 379.1k | $18.22 | $6.9M | | 05/24/2021 |
03/26/2021 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 3.2k | $5.00 | $16.2k | | 03/26/2021 |
03/26/2021 | Allogene Therapeutics, Inc. | ALLO | Grant | Common Stock | 53.6k | $0.00 | $0 | | 03/26/2021 |
03/26/2021 | Allogene Therapeutics, Inc. | ALLO | Grant | Stock Option (Right to Buy) | 199.2k | $33.78 | $6.7M | | 03/26/2021 |
03/24/2021 | UroGen Pharma Ltd. | URGN | Exercise | Stock Option (right to buy) | 3.2k | $5.00 | $16.2k | | 03/24/2021 |
10/14/2020 | Kronos Bio, Inc. | KRON | Conversion | Common Stock | 182.9k | $0.00 | $0 | By Bellco Legacy II Trust | 10/14/2020 |
10/14/2020 | Kronos Bio, Inc. | KRON | Conversion | Common Stock | 240.9k | $0.00 | $0 | By Bellco Legacy II Trust | 10/14/2020 |
10/14/2020 | Kronos Bio, Inc. | KRON | Conversion | Common Stock | 685.8k | $0.00 | $0 | By Vida Ventures, LLC | 10/14/2020 |
10/14/2020 | Kronos Bio, Inc. | KRON | Conversion | Common Stock | 1.4M | $0.00 | $0 | By Vida Ventures, LLC | 10/14/2020 |
10/14/2020 | Kronos Bio, Inc. | KRON | Conversion | Common Stock | 253.3k | $16.15 | $4.1M | By Vida Ventures, LLC | 10/14/2020 |
10/14/2020 | Kronos Bio, Inc. | KRON | Conversion | Series Seed Preferred Stock | 173.3k | $0.00 | $0 | By Bellco Legacy II Trust | 10/14/2020 |
10/14/2020 | Kronos Bio, Inc. | KRON | Conversion | Series A Preferred Stock | 1.3M | $0.00 | $0 | By Vida Ventures, LLC | 10/14/2020 |
10/14/2020 | Kronos Bio, Inc. | KRON | Conversion | Convertible Promissory Note | 0 | $16.15 | $0 | By Vida Ventures, LLC | 10/14/2020 |
10/14/2020 | Kronos Bio, Inc. | KRON | Conversion | Series A Preferred Stock | 228.3k | $0.00 | $0 | By Bellco Legacy II Trust | 10/14/2020 |
10/14/2020 | Kronos Bio, Inc. | KRON | Conversion | Series Seed Preferred Stock | 650k | $0.00 | $0 | By Vida Ventures, LLC | 10/14/2020 |
06/08/2020 | UroGen Pharma Ltd. | URGN | Grant | Stock Option (right to buy) | 10k | $28.24 | $282.4k | | 06/08/2020 |
06/04/2020 | Allogene Therapeutics, Inc. | ALLO | Purchase | Common Stock | 40k | $47.00 | $1.9M | See footnote | 06/04/2020 |
06/04/2020 | Allogene Therapeutics, Inc. | ALLO | Purchase | Common Stock | 106.4k | $47.00 | $5M | See footnote | 06/04/2020 |
03/18/2020 | Allogene Therapeutics, Inc. | ALLO | Grant | Stock Option (Right to Buy) | 379.1k | $18.22 | $6.9M | | 03/18/2020 |
|